Images	Name
	Paolo Tarantino, Italy Paolo Tarantino, MD, PhD, is a breast medical oncologist and Clinical Research Fellow at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA. He previously trained and conducted research at the European Institute of Oncology (IEO) and the University of Milan, Italy. Dr. Tarantino is internationally recognized for his work in breast cancer and early-phase drug development, with a particular focus on antibody-drug conjugates (ADCs), HER2-targeted therapies, and precision oncology. His research has contributed to advancing the understanding of HER2-low breast cancer and the development of innovative treatment strategies that are reshaping clinical practice worldwide.
	Isabel Teresa Rubio, Spain Isabel T. Rubio, MD, is Director of the Breast Surgical Oncology Unit and Coordinator of the Breast Cancer Center at Clínica Universidad de Navarra in Madrid, Spain, and Adjunct Professor of Surgery at the University of Navarra. An internationally recognized breast surgical oncologist, Dr. Rubio specializes in breast cancer surgery, with a particular focus on surgical de-escalation, neoadjuvant therapies, axillary management, and patient-reported outcomes. She currently serves as President of the European Cancer Organisation (ECO) and has previously led the European Society of Surgical Oncology (ESSO) and EUSOMA. Dr. Rubio has authored more than 190 peer-reviewed publications and is a leading contributor to international breast cancer research and clinical trials.
	Giuseppe Viale, Italy Giuseppe Viale, MD, FRCPath, is Chairman of the Department of Pathology and Laboratory Medicine at the European Institute of Oncology (IEO) IRCCS in Milan, Italy, and Emeritus Professor of Pathology at the University of Milan. An internationally recognized breast pathologist, Professor Viale has dedicated his career to advancing the biological characterization of breast cancer and serves as lead pathologist for the Breast International Group (BIG) and several international clinical trials. His research has played a pivotal role in the development of global standards for breast cancer biomarkers, including ER, PR, HER2, and Ki67 testing. Professor Viale has authored more than 700 peer-reviewed publications and is consistently recognized among Clarivate's Highly Cited Researchers in Clinical Medicine.
	Neil M. Iyengar, United States Neil M. Iyengar, MD, is a breast medical oncologist at the Winship Cancer Institute of Emory University and Associate Professor of Hematology and Oncology at Emory University School of Medicine in Atlanta, USA. He serves as Co-Director of Breast Oncology and Director of Survivorship Services, leading clinical research initiatives, therapeutic strategy development, and comprehensive survivorship care programs. Dr. Iyengar is internationally recognized for his research on breast cancer survivorship and metabolic health, with a particular focus on lifestyle interventions, nutrition, exercise, and strategies to reduce breast cancer risk and improve patient outcomes. His work has been supported by the National Cancer Institute, the American Cancer Society, the Breast Cancer Research Foundation, and other leading organizations.
	Ana Garrido-Castro, Spain Ana C. Garrido-Castro, MD, is a breast medical oncologist at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School in Boston, USA. She serves as Director of Triple-Negative Breast Cancer Research within the Division of Breast Oncology, where she leads clinical trials focused on immunotherapy, antibody-drug conjugates (ADCs), targeted therapies, and other innovative treatment strategies. Dr. Garrido-Castro is internationally recognized for her work in triple-negative breast cancer and translational clinical research, with a particular focus on developing novel therapies to improve outcomes for patients with breast cancer. She also serves as Associate Director for Breast Oncology Education at Dana-Farber, leading educational initiatives in breast oncology.
	Carmen Criscitiello, Italy Carmen Criscitiello, MD, PhD, is a breast medical oncologist and Associate Professor at Humanitas University in Milan, Italy. She serves as Head of the Breast Oncology Unit at IRCCS Humanitas Research Hospital and Head of the Medical Oncology Unit at Humanitas San Pio X. Dr. Criscitiello previously trained at the University of Naples Federico II, completed a translational research fellowship at the Institut Jules Bordet in Brussels, and held clinical and research positions at the European Institute of Oncology (IEO) in Milan. She is internationally recognized for her expertise in breast cancer, with a strong focus on translational research, precision oncology, and the development of innovative therapeutic strategies. An active leader within the European oncology community, she has authored more than 200 peer-reviewed publications and serves in editorial roles for leading oncology journals.
	Kevin Kalinsky, United States Kevin Kalinsky, MD, MS, FASCO, is a breast medical oncologist and Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, USA. He serves as Director of the Division of Medical Oncology and leads the Glenn Family Breast Center at Winship Cancer Institute, where he oversees clinical, research, and educational initiatives aimed at improving breast cancer prevention and treatment. Dr. Kalinsky is internationally recognized for his expertise in breast cancer clinical research, with a particular focus on genomics-driven precision medicine, early-phase clinical trials, and the development of novel therapeutic strategies. His contributions to advancing personalized breast cancer care have been recognized through several prestigious honors, including the NCI Cancer Clinical Investigator Team Leadership Award and the SWOG Career Engagement Award.
	Matteo Lambertini, Italy Matteo Lambertini, MD, PhD, is Director of the Medical Oncology Unit at Galliera Hospital and Associate Professor of Medical Oncology at the University of Genoa, Italy. He is an internationally recognized breast medical oncologist whose clinical and research interests focus on breast cancer in young women, fertility preservation, pregnancy-associated breast cancer, survivorship, and the optimization of treatment for special patient populations. Dr. Lambertini has authored more than 420 peer-reviewed publications and is a leading expert in oncofertility and breast cancer care. He serves as Chair of the ESMO Special Populations Committee, a member of the ASCO Annual Meeting Scientific Program Committee for Breast Cancer, Consultant Editor for the Journal of Clinical Oncology (JCO), Chair of the European School of Oncology (ESO) Certificate of Competence in Breast Cancer, and a Board Member of the International Society for Fertility Preservation.
	Michail Ignatiadis, Belgium Michail Ignatiadis, MD, PhD, is Director of the Breast Medical Oncology Clinic & Program at the Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B.), and Professor of Medical Oncology in Brussels, Belgium. He is an internationally recognized breast medical oncologist whose clinical and research interests focus on precision oncology, immunotherapy, circulating tumor DNA (ctDNA), blood-based biomarkers, and the development of innovative clinical trials in breast cancer. Prof. Ignatiadis has authored more than 130 peer-reviewed publications and has made major contributions to advancing biomarker-driven treatment strategies and translational breast cancer research. He serves as Chair of the EORTC Breast Cancer Group and is a leader in international academic clinical trials, helping to shape the future of personalized breast cancer care.
	Virginia G. Kaklamani, United States Virginia G. Kaklamani, MD, is Professor of Medicine in the Division of Hematology and Oncology at the University of Texas Health Science Center at San Antonio and Leader of the Breast Cancer Program at the Mays Cancer Center, USA. She is an internationally recognized breast medical oncologist whose clinical and research interests focus on precision medicine, targeted therapies, hereditary breast cancer, cancer genetics, obesity-related breast cancer, and the development of innovative clinical trials. Dr. Kaklamani has made significant contributions to understanding the genetic and molecular mechanisms linking obesity and breast cancer and has led numerous translational research initiatives aimed at improving personalized treatment strategies for patients with breast cancer.
	Nehmat Houssami, Australia Nehmat Houssami, MD, PhD, is Professor of Public Health at the University of Sydney and leads the Breast Cancer Clinical and Population Health Research Group at the Daffodil Centre, a joint venture of the University of Sydney and Cancer Council NSW. She is an internationally recognized clinician-researcher whose work focuses on breast cancer screening, breast imaging, early detection, artificial intelligence in cancer care, and population-based breast cancer prevention. Prof. Houssami has authored more than 390 peer-reviewed publications and is a global leader in breast screening research, contributing to evidence that has shaped international screening policies and diagnostic practices. She serves as the inaugural National Breast Cancer Foundation (NBCF) Chair in Prevention, co-Chairs the University of Sydney's AI in Cancer Care Special Interest Group, and is a National Health and Medical Research Council (NHMRC) Investigator (Leader) Fellow.
	Julie R. Gralow, United States Julie R. Gralow, MD, is Executive Vice President and Chief Medical Officer of the American Society of Clinical Oncology (ASCO) and Professor Emeritus of Medical Oncology and Global Health at the University of Washington School of Medicine, USA. She is an internationally recognized breast medical oncologist whose clinical and research interests focus on breast cancer, clinical trials, global oncology, cancer policy, survivorship, and improving access to high-quality cancer care worldwide. Dr. Gralow has played a leading role in advancing breast cancer research through cooperative clinical trials and is a prominent advocate for global cancer control and patient-centered care. As ASCO's Chief Medical Officer, she oversees research, policy, advocacy, and global initiatives that shape oncology practice and cancer care internationally.
	Ilana Schlam, United States Ilana Schlam, MD, MPH, is a breast medical oncologist and clinical researcher at the Dana-Farber Cancer Institute and Harvard Medical School in Boston, USA. She previously served on the faculty at Tufts Medical Center after completing her Hematology and Medical Oncology fellowship at MedStar Georgetown University Hospital. Dr. Schlam's research focuses on breast cancer drug development and the identification of biomarkers of response to novel therapies, with a particular emphasis on liquid biopsies and circulating tumor DNA (ctDNA). Her work aims to advance precision oncology by improving treatment selection and disease monitoring for patients with breast cancer.
	Adrienne G. Waks, United States Adrienne G. Waks, MD, is a senior breast medical oncologist at the Dana-Farber Susan F. Smith Center for Women's Cancers and serves as Associate Director of Clinical Research for Breast Oncology. She is also an Assistant Professor of Medicine at Harvard Medical School in Boston, USA. Dr. Waks conducts clinical research to develop new treatment approaches for patients with breast cancer, with a particular focus on HER2-positive disease. Her translational research aims to better understand the mechanisms of treatment response and resistance, with the goal of advancing more effective therapies for patients with breast cancer.
	Antonio Giordano, United States Antonio Giordano, MD, is a Senior Physician in Medical Oncology at the Dana-Farber Cancer Institute (DFCI), where he works in the Division of Breast Oncology. He is also an Associate Physician in Medical Oncology at Brigham and Women's Hospital (BWH) and an Assistant Professor of Medicine at Harvard Medical School (HMS) in Boston, USA. Dr. Giordano serves as Interim Director of the Center for Cancer Therapeutic Innovation at DFCI and as Breast Cancer Pathways Medical Director. His research focuses on metastatic breast cancer, with an emphasis on mechanisms of cell-cycle resistance and therapeutic strategies beyond progression on CDK4/6 inhibitors. He is the principal investigator of multiple phase I–III clinical trials, including studies evaluating novel antibody-drug conjugates (ADCs).
	Hadar Goldvaser, United States Hadar Goldvaser, MD, is an Assistant Attending in the Division of Breast Oncology at Memorial Sloan Kettering Cancer Center (MSKCC) and a member of the Department of Medicine in New York, USA. She earned her medical degree with honors from the Ruth and Bruce Rappaport Faculty of Medicine in Haifa, Israel, completed her medical oncology training at the Davidoff Cancer Center, and subsequently pursued a clinical research fellowship in breast cancer at the Princess Margaret Cancer Centre in Toronto, Canada. Prior to joining MSKCC, she served as Director of the Breast Cancer Unit at Shaare Zedek Medical Center and Associate Professor at the Hebrew University of Jerusalem in Israel. Dr. Goldvaser has authored more than 70 peer-reviewed publications and is recognized for her research focused on improving clinical care for patients with breast cancer through original investigations and rigorous meta-analyses. Her work spans HER2-positive and hormone receptor-positive breast cancer, biomarkers, cancer surveillance in BRCA mutation carriers, and the clinical and regulatory aspects of cancer drug development, with the goal of advancing evidence-based and personalized treatment strategies.
	Adam M. Brufsky, United States Adam M. Brufsky, MD, PhD, is a Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Cancer Therapeutics Program at UPMC Hillman Cancer Center. He completed his medical and doctoral training at the University of Connecticut, followed by residency and oncology fellowship training at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Brufsky is an internationally recognized leader in breast cancer medical oncology, with extensive clinical research focused on novel therapeutics, translational oncology, and precision medicine. He has authored over 400 peer-reviewed publications in leading medical journals and serves as Principal Investigator on ma
	Christos Sotiriou, Belgium Christos Sotiriou, MD, PhD, is a Full Professor and Director of the Breast Cancer Translational Research Laboratory at the Jules Bordet Institute, Université Libre de Bruxelles. He completed his medical, oncology, and doctoral training at ULB, followed by a fellowship at the National Cancer Institute (NIH). Dr. Sotiriou is an internationally recognized leader in breast cancer genomics and precision medicine, best known for pioneering the Genomic Grade Index (GGI) and uncovering fundamental insights into tumor heterogeneity, metastatic dissemination, and the tumor microenvironment. He has published over 300 peer-reviewed articles, serves as Editor-in-Chief of The Breast, and holds leadership positions across ESMO, AACR and ASCO.
	Evandro de Azambuja, Belgium Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team at the Institut Jules Bordet, HUB, Université Libre de Bruxelles in Brussels, Belgium. He earned dual PhDs from the Federal University of Rio Grande do Sul in Brazil and the Université Libre de Bruxelles. Dr. de Azambuja is an internationally recognized medical oncologist and leader in global oncology, serving as President of the Belgian Society for Medical Oncology (BSMO) and holding key leadership roles within ESMO, including former Membership Director. A prolific researcher and frequent international speaker, he has authored over 380 peer-reviewed articles and contributed extensively to major scientific and educational committees across Europe.
	Sendurai A. Mani, United States Sendurai A. Mani, PhD, is a Professor of Pathology and Medicine at the Warren Alpert Medical School of Brown University, serving as Associate Director for Translational Oncology at the Legorreta Cancer Center and Director of the Stem Cell Center. Following postdoctoral training at MIT and the Whitehead Institute, he made landmark discoveries linking epithelial-mesenchymal transition (EMT) to cancer stem cell properties and metastasis. An internationally recognized leader in cancer biology, Dr. Mani’s work integrates single-cell and spatial multi-omics to target tumor plasticity and therapeutic resistance. He has published over 80 high-impact articles with more than 37,000 citations, co-founded Iylon Precision Oncology, and is an elected Fellow of the American Association for the Advancement of Science (AAAS).
	Nadine Tung, United States Nadine Tung, MD, is a Professor of Medicine at Harvard Medical School and Director of the Executive Committee for the Breast Oncology Program at Dana-Farber Cancer Institute, as well as Director of the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center. She completed her undergraduate studies at Princeton University and received her medical degree from Harvard Medical School, followed by oncology training at Beth Israel Hospital. Dr. Tung is an internationally recognized expert in breast cancer genetics and HER2-positive breast cancer, known for pioneering work in PARP inhibitor development, managing hereditary BRCA1/2-mutated cancers, and leading landmark trials like CompassHER2 pCR. She has extensively shaped national practice guidelines through her leadership roles on ASCO's Cancer Prevention Committee and Genetics Subcommittee.
	Reva Basho, United States Reva Basho, MD, is a breast medical oncologist, clinical investigator, and Chief Medical Officer at the Ellison Medical Institute. She is an internationally recognized researcher whose work focuses on the development of novel breast cancer therapeutics, with specific expertise in targeting the PI3K pathway and advancing novel immunotherapies. Dr. Basho serves on steering committees for multiple international phase 3 clinical trials and leads a key sub-study within the National Cancer Institute’s landmark ComboMATCH trial.
	Naoto T. Ueno, United States Naoto T. Ueno, MD, PhD, FACP, is the Director and Professor of Medicine at the University of Hawaiʻi Cancer Center. He is a globally recognized leader in inflammatory breast cancer (IBC) research and has led multiple IBC clinical trials and translational research programs. His work spans targeted therapy, immunotherapy, and early drug development for breast cancer, with a particular focus on metastatic and treatment-resistant disease.
	Michael Gnant, Austria Michael Gnant, MD, FACS, FEBS, is Professor of Surgery at the Medical University of Vienna, Austria, and President of the Austrian Breast & Colorectal Cancer Study Group (ABCSG). A leading expert in breast cancer and surgical oncology, he has dedicated his career to advancing clinical research in breast cancer through international clinical trials and translational research. His areas of expertise include immunotherapy, endocrine therapy, bone-targeted treatments, tumor dormancy, and precision medicine, with research that has helped improve treatment strategies and outcomes for patients with breast cancer.
	Claudine Isaacs, United States Claudine Isaacs is a Professor of Medicine and Oncology at Georgetown University and serves as Associate Director for Clinical Research and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC), USA. She also serves as Medical Director of the Fisher Center for Hereditary Cancer Research. Dr. Isaacs is widely recognized for her contributions to breast cancer clinical research, with a particular focus on early-stage and metastatic breast cancer, hereditary breast cancer, endocrine resistance, and translational oncology. She has led and contributed to numerous landmark clinical trials that have advanced treatment approaches and improved outcomes for patients with breast cancer.
	Véronique Debien, France Véronique Debien is a medical oncologist and Head of the Early Phase Trials Unit at Institut Bergonié in Bordeaux, France. She also chairs the institutional Molecular Tumor Board, focusing on the integration of molecular profiling into personalized treatment strategies and clinical trial selection. Dr. Debien is recognized for her expertise in early-phase clinical research and innovative therapies, with particular interests in antibody-drug conjugates, targeted therapies, immunotherapy, precision oncology, and HER2-positive breast cancer. Her research and clinical work contribute to advancing personalized treatment approaches and the development of novel therapeutic strategies in breast cancer.
	Giovanna Rossi, Italy Giovanna Rossi is a medical oncologist and PhD candidate in Clinical Research at the University of Milan, Italy. She has trained and conducted research at leading institutions in Italy, the United States, and Belgium, including the Veneto Oncology Institute, Northwestern University of Chicago, Thomas Jefferson University of Philadelphia, and the European Organisation for Research and Treatment of Cancer (EORTC). Dr. Rossi is recognized for her work in breast cancer clinical and translational research, with particular expertise in liquid biopsy, circulating tumor DNA, precision medicine, and emerging biomarkers. Her research has contributed to advancing personalized approaches in breast cancer management and the development of innovative strategies for treatment monitoring and patient care.
	Frederick Howard, United States Frederick Howard, MD, is an Assistant Professor of Medicine and breast medical oncologist at the University of Chicago. His research focuses on using artificial intelligence and computational methods to improve breast cancer care. Dr. Howard’s research group develops predictive models and digital pathology biomarkers to guide treatment decisions, assess recurrence risk, and identify patients most likely to benefit from therapy. His work also examines disparities in cancer outcomes and seeks to ensure that emerging precision-medicine technologies perform reliably across diverse populations.
	Ashley Marumoto, United States Ashley Marumoto, MD, is a breast surgical oncologist and Director of Breast Health at Kuakini Medical Center in Honolulu, Hawaii. She serves as Clinical Faculty at the University of Hawaii Cancer Center and Clinical Assistant Professor in the Department of Surgery at the University of Hawaii John A. Burns School of Medicine. Dr. Marumoto completed her general surgery residency at the University of Hawaiʻi, followed by a fellowship in breast surgical oncology at Cedars-Sinai Medical Center in Los Angeles, California. In addition to treating patients, she is actively involved in medical education and participates in clinical research. She is also committed to developing future healthcare leaders through her work with the Japan Team Oncology Program.
	Megan Tesch, Canada Megan Tesch, MD, MPH, is a medical oncologist in the Breast Oncology Center at Dana-Farber Cancer Institute in Boston, USA, and an Instructor in Medicine at Harvard Medical School. She completed her medical training at Memorial University of Newfoundland, Canada, followed by residency and oncology training in Canada and at Dana-Farber Cancer Institute, where she also served as a fellow in Breast Oncology. Dr. Tesch specializes in the care of patients with breast cancer, with a particular focus on young adults with breast cancer. Her clinical and research interests center on young-onset breast cancer, investigating the unique clinical and biological factors that influence outcomes and contribute to disparities among younger patients. She is actively involved in clinical research aimed at improving treatment strategies and long-term outcomes for young adults with breast cancer.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Mammo 2026: Global Breast Cancer Virtual Congress

Overview

Scientific Program Overview

Scientific Leadership

Speakers

Paolo Tarantino, Italy

Isabel Teresa Rubio, Spain

Giuseppe Viale, Italy

Neil M. Iyengar, United States

Ana Garrido-Castro, Spain

Carmen Criscitiello, Italy

Kevin Kalinsky, United States

Matteo Lambertini, Italy

Michail Ignatiadis, Belgium

Virginia G. Kaklamani, United States

Nehmat Houssami, Australia

Julie R. Gralow, United States

Ilana Schlam, United States

Adrienne G. Waks, United States

Antonio Giordano, United States

Hadar Goldvaser, United States

Adam M. Brufsky, United States

Christos Sotiriou, Belgium

Evandro de Azambuja, Belgium

Sendurai A. Mani, United States

Nadine Tung, United States

Reva Basho, United States

Naoto T. Ueno, United States

Michael Gnant, Austria

Claudine Isaacs, United States

Véronique Debien, France

Giovanna Rossi, Italy

Frederick Howard, United States

Ashley Marumoto, United States

Megan Tesch, Canada

Scientific Leadership

Speakers

Paolo Tarantino, Italy

Isabel Teresa Rubio, Spain

Giuseppe Viale, Italy

Neil M. Iyengar, United States

Ana Garrido-Castro, Spain

Carmen Criscitiello, Italy

Kevin Kalinsky, United States

Matteo Lambertini, Italy

Michail Ignatiadis, Belgium

Virginia G. Kaklamani, United States

Nehmat Houssami, Australia

Julie R. Gralow, United States

Ilana Schlam, United States

Adrienne G. Waks, United States

Antonio Giordano, United States

Hadar Goldvaser, United States

Adam M. Brufsky, United States

Christos Sotiriou, Belgium

Evandro de Azambuja, Belgium

Sendurai A. Mani, United States

Nadine Tung, United States

Reva Basho, United States

Naoto T. Ueno, United States

Michael Gnant, Austria

Claudine Isaacs, United States

Véronique Debien, France

Giovanna Rossi, Italy

Frederick Howard, United States

Ashley Marumoto, United States

Megan Tesch, Canada

Contact Us

News & Updates

European School of Oncology

Sitemap

Hemostasis Today

Fertility News

Oncodaily Journal